*GI symptoms comparable to other NSAIDs, including diarrhea, dyspepsia, and abdominal pain. In patients treated chronically with NSAID therapy, serious GI toxicity such as perforation, ulceration, and bleeding can occur.

As with other NSAIDs, rare renal and hepatic reactions have been reported. Please see precautions section of prescribing information.

Contraindicated in patients who are hypersensitive to aspirin or other NSAIDs.

Please see brief summary of prescribing information on adjacent page.

into everyday

activities

Relafen® provides potent anti-inflammatory relief of RA and OA with less than 1% incidence of peptic ulcer*

Relafen helps patients meet the challenges of everyday tasks by significantly reducing joint pain, morning stiffness, and other symptoms associated with RA and OA.[1] And, *Relafen* safely meets the challenges of living with arthritis by minimizing the risk of serious GI damage. In fact, long-term studies lasting up to 2 years indicate *Relafen* has a less than 1% incidence of peptic ulcer.*

Effective relief with a low incidence of peptic ulcer*

RELAFEN®
NABUMETONE

Reference: 1. Morgan GJ, Poland M, DeLapp RE. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. *Am J Med.* 1993;95(suppl 2A):19S-27S.

RELAFEN®

brand of nabumetone

Brief Summary: Consult full prescribing information before using.

CLINICAL PHARMACOLOGY: *Relafen* is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic properties in pharmacologic studies. As with other nonsteroidal anti-inflammatory agents, its mode of action is not known. However, the ability to inhibit prostaglandin synthesis may be involved in the anti-inflammatory effect.

The parent compound is a prodrug, which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid (6MNA), a potent inhibitor of prostaglandin synthesis.

INDICATIONS AND USAGE: Acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.

CONTRAINDICATIONS: Patients (1) who have previously exhibited hypersensitivity to it; (2) in whom *Relafen*, aspirin or other NSAIDs induce asthma, urticaria or other allergic-type reactions.

WARNINGS: Remain alert for ulceration and bleeding in patients treated chronically, even in the absence of previous G.I. tract symptoms.

In controlled clinical trials involving 1,677 patients treated with *Relafen* (1,140 followed for one year and 927 for two years), the cumulative incidence of peptic ulcers was 0.3% (95% CI; 0%, 0.6%) at three to six months, 0.5% (95% CI; 0.1%, 0.9%) at one year and 0.8% (95% CI; 0.3%, 1.3%) at two years. Inform patients of the signs and symptoms of serious G.I. toxicity and what steps to take if they occur. In patients with active peptic ulcer, weigh the benefits of *Relafen* therapy against possible hazards, institute an appropriate ulcer treatment regimen and monitor the patients' progress carefully.

In considering the use of relatively large doses (within the recommended dosage range), anticipate benefit sufficient to offset the potential increased risk of G.I. toxicity.

PRECAUTIONS: Because nabumetone undergoes extensive hepatic metabolism, no adjustment of *Relafen* dosage is generally necessary in patients with renal insufficiency. However, as with all NSAIDs, monitor patients with impaired renal function more closely than patients with normal renal function.

Evaluate patients with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, for evidence of the development of a more severe hepatic reaction while on *Relafen* therapy. If abnormal liver tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue *Relafen*. Use *Relafen* cautiously in patients with severe hepatic impairment.

As with other NSAIDs, use *Relafen* cautiously in patients with a history of congestive heart failure, hypertension or other conditions predisposing to fluid retention.

Based on U.V. light photosensitivity testing, *Relafen* may be associated with more reactions to sun exposure than might be expected based on skin tanning types.

Physicians may wish to discuss with their patients the potential risks (see WARNINGS, PRECAUTIONS and ADVERSE REACTIONS) and likely benefits of NSAID treatment, particularly when the drugs are used for less serious conditions where treatment without NSAIDs may represent an acceptable alternative to both the patient and the physician.

Exercise caution when administering *Relafen* with warfarin since interactions have been seen with other NSAIDs.

In two-year studies conducted in mice and rats, nabumetone had no statistically significant tumorigenic effect. Nabumetone did not show mutagenic potential in the Ames test and mouse micronucleus test *in vivo*. However, nabumetone- and 6MNA-treated lymphocytes in culture showed chromosomal aberrations at 80 mcg/mL and higher concentrations (equal to the average human exposure to *Relafen* at the maximum recommended dose).

Nabumetone did not impair fertility of male or female rats treated orally at doses of 320 mg/kg/day before mating.

Pregnancy Category C: Nabumetone did not cause any teratogenic effect in rats given up to 400 mg/kg and in rabbits up to 300 mg/kg orally. However, increased post-implantation loss was observed in rats at 100 mg/kg orally and at higher doses (equal to the average human exposure to 6MNA at the maximum recommended human dose). There are no adequate, well-controlled studies in pregnant women. Use the drug during pregnancy only if clearly needed. Because of the known effect of prostaglandin-synthesis-inhibiting drugs on the human fetal cardiovascular system (closure of ductus arteriosus), use of *Relafen* during the third trimester of pregnancy is not recommended.

The effects of *Relafen* on labor and delivery in women are not known. As with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia and delayed parturition occurred in rats treated throughout pregnancy.

It is not known whether nabumetone or its metabolites are excreted in human milk; however, 6MNA is excreted in the milk of lactating rats. Because of the possible adverse effects of prostaglandin-synthesis-inhibiting drugs on neonates, *Relafen* is not recommended for use in nursing mothers.

Safety and efficacy in children have not been established.

Of the 1,677 patients in U.S. clinical studies who were treated with *Relafen*, 411 patients (24%) were 65 years of age or older; 22 patients (1%) were 75 years of age or older. No overall differences in efficacy or safety were observed between these older patients and younger ones. Similar results were observed in a one-year, non-U.S. postmarketing surveillance study of 10,800 *Relafen* patients, of whom 4,577 patients (42%) were 65 years of age or older.

ADVERSE REACTIONS: Incidence ≥1%—Probably Causally Related—Diarrhea (14%), dyspepsia (13%), abdominal pain (12%), constipation*, flatulence*, nausea*, positive stool guaiac*, dry mouth, gastritis, stomatitis, vomiting, dizziness*, headache*, fatigue, increased sweating, insomnia, nervousness, somnolence, pruritus*, rash*, tinnitus*, edema*.
*Incidence of reported reaction between 3% and 9%. Reactions occurring in 1% to 3% of the patients are unmarked.

Incidence <1%—Probably Causally Related†—Anorexia, cholestatic jaundice, duodenal ulcer, dysphagia, gastric ulcer, gastroenteritis, gastrointestinal bleeding, increased appetite, liver function abnormalities, melena, asthenia, agitation, anxiety, confusion, depression, malaise, paresthesia, tremor, vertigo, bullous eruptions, photosensitivity, urticaria, pseudoporphyria cutanea tarda, *toxic epidermal necrolysis*, vasculitis, weight gain, dyspnea, *eosinophilic pneumonia, hypersensitivity pneumonitis*, albuminuria, azotemia, *hyperuricemia, interstitial nephritis, nephrotic syndrome, vaginal bleeding*, abnormal vision, *anaphylactoid reaction, anaphylaxis*, angioneurotic edema.

Incidence <1%—Causal Relationship Unknown†—Bilirubinuria, duodenitis, eructation, gallstones, gingivitis, glossitis, pancreatitis, rectal bleeding, nightmares, acne, alopecia, *erythema multiforme, Stevens-Johnson Syndrome*, angina, arrhythmia, hypertension, myocardial infarction, palpitations, syncope, thrombophlebitis, asthma, cough, dysuria, hematuria, impotence, renal stones, taste disorder, fever, chills, anemia, leukopenia, granulocytopenia, thrombocytopenia, hyperglycemia, hypokalemia, weight loss.
†Adverse reactions reported only in worldwide postmarketing experience or in the literature, not seen in clinical trials, are considered rarer and are italicized.

OVERDOSAGE: If acute overdose occurs, empty the stomach by vomiting or lavage and institute general supportive measures as necessary. Activated charcoal, up to 60 grams, may effectively reduce nabumetone absorption. Coadministration of nabumetone with charcoal to man has resulted in an 80% decrease in maximum plasma concentrations of the active metabolite.

One overdose occurred in a 17-year-old female patient who had a history of abdominal pain and was hospitalized for increased abdominal pain following ingestion of 30 *Relafen* tablets (15 grams total). Stools were negative for occult blood and there was no fall in serum hemoglobin concentration. The patient had no other symptoms. She was given an H_2-receptor antagonist and discharged from the hospital without sequelae.

DOSAGE AND ADMINISTRATION: Recommended starting dose: 1000 mg taken as a single dose with or without food. Some patients may obtain more symptomatic relief from 1500 mg to 2000 mg daily. Dosages over 2000 mg daily have not been studied. Use the lowest effective dose for chronic treatment.

HOW SUPPLIED: Tablets: Oval-shaped, film-coated: 500 mg–white, imprinted with the product name RELAFEN and 500, in bottles of 100 and 500, and in Single Unit Packages of 100 (intended for institutional use only); 750 mg–beige, imprinted with the product name RELAFEN and 750, in bottles of 100 and 500, and in Single Unit Packages of 100 (intended for institutional use only).

Store at controlled room temperature (59° to 86°F) in well-closed container; dispense in light-resistant container.

500 mg 100's: NDC 0029-4851-20
500 mg 500's: NDC 0029-4851-25
500 mg SUP 100's: NDC 0029-4851-21
750 mg 100's: NDC 0029-4852-20
750 mg 500's: NDC 0029-4852-25
750 mg SUP 100's: NDC 0029-4852-21

BRS-RL:L7

SmithKline Beecham Pharmaceuticals

Philadelphia, PA 19101

Ambien® (zolpidem tartrate)

References: 1. Data on file, Searle. 2. Vogel G, Scharf M, Walsh J, et al. Effects of chronically administered zolpidem on the sleep of healthy insomniacs. *Sleep Research.* 1989;18:80. Abstract. 3. Walsh JK, Schweitzer PK, Sugerman JL, et al. Transient insomnia associated with a 3-hour phase advance of sleep time and treatment with zolpidem. *J Clin Psychopharmacol.* 1990;10:184-189.

BRIEF SUMMARY

INDICATIONS AND USAGE

Ambien (zolpidem tartrate) is indicated for the short-term treatment of insomnia. Hypnotics should generally be limited to 7 to 10 days of use, and reevaluation of the patient is recommended if they are to be taken for more than 2 to 3 weeks.

Ambien should not be prescribed in quantities exceeding a 1-month supply (see *Warnings*).

CONTRAINDICATIONS

None known.

WARNINGS

Since sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness which should be evaluated. Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative/hypnotic drugs, including Ambien. Because some of the important adverse effects of Ambien appear to be dose related (see *Precautions* and *Dosage and Administration*), it is important to use the smallest possible effective dose, especially in the elderly.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of sedative/hypnotics. Some of these changes may be characterized by decreased inhibition (eg, aggressiveness and extroversion that seemed out of character), similar to effects produced by alcohol and other CNS depressants. Other reported behavioral changes have included bizarre behavior, agitation, hallucinations, and depersonalization. Amnesia and other neuropsychiatric symptoms may occur unpredictably. In primarily depressed patients, worsening of depression, including suicidal thinking, has been reported in association with the use of sedative/hypnotics.

It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above are drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.

Following the rapid dose decrease or abrupt discontinuation of sedative/hypnotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs (see *Drug Abuse and Dependence*).

Ambien, like other sedative/hypnotic drugs, has CNS-depressant effects. Due to the rapid onset of action, Ambien should only be ingested immediately prior to going to bed. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle after ingesting the drug, including potential impairment of the performance of such activities that may occur the day following ingestion of Ambien. Ambien showed additive effects when combined with alcohol and should not be taken with alcohol. Patients should also be cautioned about possible combined effects with other CNS-depressant drugs. Dosage adjustments may be necessary when Ambien is administered with such agents because of the potentially additive effects.

PRECAUTIONS

General

Use in the elderly and/or debilitated patients: Impaired motor and/or cognitive performance after repeated exposure or unusual sensitivity to sedative/hypnotic drugs is a concern in the treatment of elderly and/or debilitated patients. Therefore, the recommended Ambien dosage is 5 mg in such patients (see *Dosage and Administration*) to decrease the possibility of side effects. These patients should be closely monitored.

Use in patients with concomitant illness: Clinical experience with Ambien in patients with concomitant systemic illness is limited. Caution is advisable in using Ambien in patients with diseases or conditions that could affect metabolism or hemodynamic responses. Although preliminary studies did not reveal respiratory depressant effects at hypnotic doses of Ambien in normals, precautions should be observed if Ambien is prescribed to patients with compromised respiratory function, since sedative/hypnotics have the capacity to depress respiratory drive. Post-marketing reports of respiratory insufficiency, most of which involved patients with pre-existing respiratory impairment, have been received. Data in end-stage renal failure patients repeatedly treated with Ambien did not demonstrate drug accumulation or alterations in pharmacokinetic parameters. No dosage adjustment in renally impaired patients is required; however, these patients should be closely monitored (see *Pharmacokinetics*). A study in subjects with hepatic impairment did reveal prolonged elimination in this group; therefore, treatment should be initiated with 5 mg in patients with hepatic compromise, and they should be closely monitored.

Use in depression: As with other sedative/hypnotic drugs, Ambien should be administered with caution to patients exhibiting signs or symptoms of depression. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdosage is more common in this group of patients; therefore, the least amount of drug that is feasible should be prescribed for the patient at any one time.

Information for patients: Patient information is printed in the complete prescribing information and is available in pads for distribution to patients.

Laboratory tests: There are no specific laboratory tests recommended.

Drug interactions

CNS-active drugs: Ambien was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs. A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. Imipramine in combination with zolpidem produced no pharmacokinetic interaction other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance. The lack of a drug interaction following single-dose administration does not predict a lack following chronic administration.

An additive effect on psychomotor performance between alcohol and zolpidem was demonstrated.

Since the systematic evaluations of Ambien in combination with other CNS-active drugs have been limited, careful consideration should be given to the pharmacology of any CNS-active drug to be used with zolpidem. Any drug with CNS-depressant effects could potentially enhance the CNS-depressant effects of zolpidem.

Other drugs: A study involving cimetidine/zolpidem and ranitidine/zolpidem combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem. Zolpidem had no effect on digoxin kinetics and did not affect prothrombin time when given with warfarin in normal subjects. Zolpidem's sedative/hypnotic effect was reversed by flumazenil; however, no significant alterations in zolpidem pharmacokinetics were found.

Drug/Laboratory test interactions: Zolpidem is not known to interfere with commonly employed clinical laboratory tests.

Carcinogenesis, mutagenesis, impairment of fertility

Carcinogenesis: Zolpidem was administered to rats and mice for 2 years at dietary dosages of 4, 18, and 80 mg/kg/day. In mice, these doses are 26 to 520 times or 2 to 35 times the maximum 10-mg human dose on a mg/kg or mg/m² basis, respectively. In rats these doses are 43 to 876 times or 6 to 115 times the maximum 10-mg human dose on a mg/kg or mg/m² basis, respectively. No evidence of carcinogenic potential was observed in mice. Renal liposarcomas were seen in 4/100 rats (3 males, 1 female) receiving 80 mg/kg/day and a renal lipoma was observed in one male rat at the 18 mg/kg/day dose. Incidence rates of lipoma and liposarcoma for zolpidem were comparable to those seen in historical controls and the tumor findings are thought to be a spontaneous occurrence.

Mutagenesis: Zolpidem did not have mutagenic activity in several tests including the Ames test, genotoxicity in mouse lymphoma cells in vitro, chromosomal aberrations in cultured human lymphocytes, unscheduled DNA synthesis in rat hepatocytes in vitro, and the micronucleus test in mice.

Impairment of fertility: In a rat reproduction study, the high dose (100 mg base/kg) of zolpidem resulted in irregular estrus cycles and prolonged precoital intervals, but there was no effect on male or female fertility after daily oral doses of 4 to 100 mg base/kg or 5 to 130 times the recommended human dose in mg/m². No effects on any other fertility parameters were noted.

Pregnancy

Category B. Studies to assess the effects of zolpidem on human reproduction and development have not been conducted.

Teratology studies were conducted in rats and rabbits.

In rats, adverse maternal and fetal effects occurred at 20 and 100 mg base/kg and included dose-related maternal lethargy and ataxia and a dose-related trend to incomplete ossification of fetal skull bones.

In rabbits, dose-related maternal sedation and decreased weight gain occurred at all doses tested. At the high dose, 16 mg base/kg, there was an increase in postimplantation fetal loss and underossification of sternebrae in viable fetuses.

This drug should be used during pregnancy only if clearly needed.

Nonteratogenic effects: Studies to assess the effects on children whose mothers took zolpidem during pregnancy have not been conducted. However, children born of mothers taking sedative/hypnotic drugs may be at some risk for withdrawal symptoms from the drug during the postnatal period. In addition, neonatal flaccidity has been reported in infants born of mothers who received sedative/hypnotic drugs during pregnancy.

Labor and delivery: Ambien has no established use in labor and delivery.

Nursing mothers: Studies in lactating mothers indicate that between 0.004 and 0.019% of the total administered dose is excreted into milk, but the effect of zolpidem on the infant is unknown.

The use of Ambien in nursing mothers is not recommended.

Safety and effectiveness in children below the age of 18 have not been established.

ADVERSE REACTIONS

Associated with discontinuation of treatment: Approximately 4% of 1,701 patients who received zolpidem at all doses (1.25 to 90 mg) in U.S. premarketing clinical trials discontinued treatment because of an adverse clinical event. Events most commonly associated with discontinuation from U.S. trials were daytime drowsiness (0.5%), dizziness (0.4%), headache (0.5%), nausea (0.6%), and vomiting (0.5%).

Approximately 6% of 1,320 patients who received zolpidem at all doses (5 to 50 mg) in similar foreign trials discontinued treatment because of an adverse event. Events most commonly associated with discontinuation from these trials were daytime drowsiness (1.6%), amnesia (0.6%), dizziness (0.6%), headache (0.6%), and nausea (0.6%).

Incidence in controlled clinical trials

Most commonly observed adverse events in controlled trials: During short-term treatment (up to 10 nights) with Ambien at doses up to 10 mg, the most commonly observed adverse events associated with the use of zolpidem and seen at statistically significant differences from placebo-treated patients were drowsiness (reported by 2% of zolpidem patients), dizziness (1%), and diarrhea (1%). During longer-term treatment (28 to 35 nights) with zolpidem at doses up to 10 mg, the most commonly observed adverse events associated with the use of zolpidem and seen at statistically significant differences from placebo-treated patients were dizziness (5%) and drugged feelings (3%).

Incidence of Treatment-Emergent Adverse Experiences in Short-term Placebo-Controlled Clinical Trials
(Percentage of patients reporting)

Body System/ Adverse Event*	Zolpidem (≤ 10 mg) (N=685)	Placebo (N=473)
Central and Peripheral Nervous System		
Headache	7	6
Drowsiness	2	–
Dizziness	1	–
Gastrointestinal System		
Nausea	2	3
Diarrhea	1	–
Musculoskeletal System		
Myalgia	1	2

*Events reported by at least 1% of Ambien patients are included.

Incidence of Treatment-Emergent Adverse Experiences in Long-term Placebo-Controlled Clinical Trials
(Percentage of patients reporting)

Body System/ Adverse Event*	Zolpidem (≤ 10 mg) (N=152)	Placebo (N=161)
Autonomic Nervous System		
Dry mouth	3	1
Body as a Whole		
Allergy	4	1
Back pain	3	2
Influenza-like symptoms	2	–
Chest pain	1	–
Fatigue	1	2
Cardiovascular System		
Palpitation	2	–
Central and Peripheral Nervous System		
Headache	19	22
Drowsiness	8	5
Dizziness	5	1
Lethargy	3	1
Drugged feeling	3	–
Lightheadedness	2	1
Depression	2	1
Abnormal dreams	1	–
Amnesia	1	–
Anxiety	1	1
Nervousness	1	3
Sleep disorder	1	–
Gastrointestinal System		
Nausea	6	6
Dyspepsia	5	6
Diarrhea	3	2
Abdominal pain	2	2
Constipation	2	1
Anorexia	1	1
Vomiting	1	1
Immunologic System		
Infection	1	1
Musculoskeletal System		
Myalgia	7	7
Arthralgia	4	4

Incidence of Treatment-Emergent Adverse Experiences in Long-term Placebo-Controlled Clinical Trials (Cont'd)
(Percentage of patients reporting)

Body System/ Adverse Event*	Zolpidem (≤ 10 mg) (N=152)	Placebo (N=161)
Respiratory System		
Upper respiratory infection	5	6
Sinusitis	4	2
Pharyngitis	3	1
Rhinitis	1	3
Skin and Appendages		
Rash	2	1
Urogenital System		
Urinary tract infection	2	2

*Events reported by at least 1% of patients treated with Ambien.

There is evidence from dose comparison trials suggesting a dose relationship for many of the adverse events associated with zolpidem use, particularly for certain CNS and gastrointestinal adverse events.

Adverse events are further classified and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in greater than 1/100 subjects; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare events are those occurring in less than 1/1,000 patients.

Frequent: abdominal pain, amnesia, ataxia, confusion, depression, diarrhea, diplopia, dizziness, dreaming abnormal, drowsiness, drugged feeling, dry mouth, dyspepsia, euphoria, fatigue, headache, insomnia, lethargy, lightheadedness, myalgia, nausea, upper respiratory infection, vertigo, vision abnormal, vomiting.

Infrequent: agitation, allergy, anorexia, anxiety, arthralgia, arthritis, asthenia, back pain, bronchitis, cerebrovascular disorder, chest pain, constipation, coughing, cystitis, decreased cognition, detached, difficulty concentrating, dysarthria, dysphagia, dyspnea, edema, emotional lability, eye irritation, falling, fever, flatulence, gastroenteritis, hallucination, hiccup, hyperglycemia, hypertension, hypoaesthesia, infection, influenza-like symptoms, malaise, menstrual disorder, migraine, nervousness, pallor, palpitation, paresthesia, pharyngitis, postural hypotension, pruritus, rash, rhinitis, scleritis, SGPT increased, sinusitis, sleep disorder, sleeping (after daytime dosing), stupor, sweating increased, tachycardia, taste perversion, tinnitus, tooth disorder, trauma, tremor, urinary incontinence, urinary tract infection, vaginitis.

Rare: abdominal body sensation, abscess, acne, acute renal failure, aggressive reaction, allergic reaction, allergy aggravated, anaphylactic shock, anemia, appetite increased, arrhythmia, arteritis, arthrosis, bilirubinemia, breast fibroadenosis, breast neoplasm, breast pain female, bronchospasm, bullous eruption, BUN increased, circulatory failure, corneal ulceration, delusion, dementia, depersonalization, dermatitis, dysphasia, dysuria, edema periorbital, enteritis, epistaxis, eructation, esophagospasm, ESR increased, extrasystoles, eye pain, face edema, feeling strange, flushing, furunculosis, gastritis, glaucoma, gout, hemorrhoids, hepatic function abnormal, herpes simplex, herpes zoster, hot flashes, hypercholesteremia, hyperhemoglobinemia, hyperlipidemia, hypertension aggravated, hypotension, hypotonia, hypoxia, hysteria, illusion, impotence, injection site inflammation, intestinal obstruction, intoxicated feeling, lacrimation abnormal, laryngitis, leg cramps, leukopenia, libido decreased, lymphadenopathy, macrocytic anemia, manic reaction, micturition frequency, muscle weakness, myocardial infarction, neuralgia, neuritis, neuropathy, neurosis, otitis externa, otitis media, pain, panic attack, paresis, personality disorder, phlebitis, photopsia, photosensitivity reaction, pneumonia, polyuria, pulmonary edema, pulmonary embolism, purpura, pyelonephritis, rectal hemorrhage, renal pain, restless legs, rigors, saliva altered, sciatica, SGOT increased, somnambulism, suicide attempt, syncope, tendinitis, tenesmus, tetany, thinking abnormal, thirst, tolerance increased, tooth caries, urinary retention, urticaria, varicose veins, ventricular tachycardia, weight decrease, yawning.

DRUG ABUSE AND DEPENDENCE

Controlled substance: Schedule IV.

Abuse and dependence: Studies of abuse potential in former drug abusers found that the effects of single doses of zolpidem tartrate 40 mg were similar, but not identical, to diazepam 20 mg, while zolpidem tartrate 10 mg was difficult to distinguish from placebo.

Sedative/hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. These reported symptoms range from mild dysphoria and insomnia to a withdrawal syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremors, and convulsions. The U.S. clinical trial experience from zolpidem does not reveal any clear evidence for withdrawal syndrome. Nevertheless, the following adverse events included in DSM-III-R criteria for uncomplicated sedative/hypnotic withdrawal were reported at an incidence of ≤ 1% during U.S. clinical trials following placebo substitution occurring within 48 hours following last zolpidem treatment: fatigue, nausea, flushing, lightheadedness, uncontrolled crying, emesis, stomach cramps, panic attack, nervousness, and abdominal discomfort.

Individuals with a history of addiction to, or abuse of, drugs or alcohol are at risk of habituation and dependence; they should be under careful surveillance when receiving any hypnotic.

OVERDOSAGE

Signs and symptoms: In European postmarketing reports of overdose with zolpidem alone, impairment of consciousness has ranged from somnolence to light coma, with one case each of cardiovascular and respiratory compromise. Individuals have fully recovered from zolpidem tartrate overdoses up to 400 mg (40 times the maximum recommended dose). Overdose cases involving multiple CNS-depressant agents, including zolpidem, have resulted in more severe symptomatology, including fatal outcomes.

Recommended treatment: General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Flumazenil may be useful. Respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Sedating drugs should be withheld following zolpidem overdosage. Zolpidem is not dialyzable.

The possibility of multiple drug ingestion should be considered.

Caution: Federal law prohibits dispensing without prescription.

4/11/94

Manufactured and distributed by
G.D. Searle & Co.
Chicago, IL 60680
by agreement with
Lorex Pharmaceuticals
Skokie, IL

Address medical inquiries to:
G.D. Searle & Co.
Medical & Scientific Information Department
4901 Searle Parkway
Skokie, IL 60077

SEARLE *Box 5110*
Chicago, IL 60680-5110

Aug 1994
P94AB9907T

AMBIEN®
(ZOLPIDEM TARTRATE) C-IV
5-MG & 10-MG TABLETS

From a unique chemical class of non-benzodiazepine sleep agents

More sleep
Total sleep time is significantly increased compared with placebo. Patients fall asleep quickly; generally within 20 to 30 minutes.[1-3]

Better sleep
Awakenings were reduced, compared to placebo.

Through the night
No evidence of increased wakefulness during the last third of the night. Normal sleep stages are generally preserved[1] (clinical significance unknown).

With no objective evidence of tolerance or rebound insomnia
In studies of up to 35 consecutive nights at recommended doses.[1,2]

Favorable safety and tolerability profile

Adverse events with dosages of ≤ 10 mg that were statistically significant vs placebo

Short-term: ≤10 nights		Long-term: 28 to 35 nights	
drowsiness	2%	dizziness	5%
dizziness	1%	drugged feelings	3%
diarrhea	1%		

AMBIEN®
(ZOLPIDEM TARTRATE) C-IV 5-MG & 10-MG TABLETS

In the short-term treatment of insomnia

First in a unique chemical class of non-benzodiazepine sleep agents

Please see references and brief summary of prescribing information on the last page of this advertisement.

ARCHIVES
OF
FAMILY MEDICINE

The ARCHIVES OF FAMILY MEDICINE is a member of the consortium of AMA journals listed below. The ARCHIVES reaches more than 81 500 readers in family and general practice each month, in addition to paid subscribers. The complete text of all AMA journals is available online from Dialog Information Services and Information Access Company.

The Journal of the American Medical Association (JAMA)
Archives of Dermatology
Archives of Family Medicine
Archives of General Psychiatry
Archives of Internal Medicine
Archives of Neurology
Archives of Ophthalmology
Archives of Otolaryngology—Head & Neck Surgery
Archives of Pediatrics & Adolescent Medicine
Archives of Surgery

The ARCHIVES OF FAMILY MEDICINE (ISSN 1063-3987) is published monthly by the American Medical Association, 515 N State St, Chicago, IL 60610, and is an official publication of the Association. Second-class postage rates paid at Chicago and at additional mailing office. GST registration number R126 225 556. Canada Post International Publications Mail (Canadian Distribution) Sales Agreement No. 319600. Printed in the USA.

SUBSCRIPTION RATES—The subscription rates for the ARCHIVES OF FAMILY MEDICINE are as follows: $95 for 1 year, $190 for 2 years in the United States and US possessions; in the Americas, 1 year, $130, 2 years, $260; the rest of the world, 1 year, £90, 2 years, £180. The institution rates are as follows: $105 for 1 year, $210 for 2 years in the United States and US possessions; in the Americas, 1 year, $140, 2 years, $280; the rest of the world, 1 year, £97, 2 years, £194. Rates for subscriptions for delivery to Japan are available through our exclusive agents—contact the publisher. Special rates for residents and medical students in the United States and US possessions are available. Address inquiries to Subscriber Services Center, American Medical Association, PO Box 10945, Chicago, IL 60610. Phone: (800) 262-2350. Fax: (312) 464-5831. For mailing addresses outside the United States and US possessions, see International Subscription Information.

CHANGE OF ADDRESS—POSTMASTER, send all address changes to ARCHIVES OF FAMILY MEDICINE, c/o Subscriber Services, American Medical Association, 515 N State St, Chicago, IL 60610. Please notify us of address change at least 6 weeks in advance to ensure uninterrupted service. Include both old and new addresses, a recent mailing label, and new ZIP code. For mailing addresses outside the US and US possessions, see International Subscription Information.

SUBSCRIBER SERVICES—For information about subscribing to any of the AMA publications, change of address, missing issues, or purchasing back issues, please contact Subscriber Services Center, American Medical Association, PO Box 10945, Chicago, IL 60610, or call (312) 670-SUBS (670-7827) between 8:30 AM and 4:30 PM CST. Fax: (312) 464-5831. For mailing addresses outside the US and US possessions, see International Subscription Information.

INTERNATIONAL SUBSCRIPTION INFORMATION—Subscriptions outside the United States and US possessions are served according to geographic region. Please address correspondence to the following two offices based on delivery address: 1) For delivery in North America, Central America, and South America, contact Subscriber Services Center, AMA, PO Box 10945, Chicago, IL 60610, USA. Phone: 1-312-760-7827. Fax: 1-312-464-5831; 2) For delivery outside the Americas, contact JAMA & Archives Journals Reader Services Centre, PO Box 299, London, England WC1H 9TD. Phone: 44-(0)71-383 6270. Fax: 44-(0)71-383 6402.

REPRINTS—Authors place their reprint order at the time the edited typescript is reviewed and should allow 4 to 6 weeks for delivery following publication. Requests for individual reprints should be sent directly to the author at the address shown in the article.

For bulk reprint orders for commercial distribution, please contact Mark Kuhns, 600 Third Ave, New York, NY 10016. Phone: (212) 867-6640. Fax: (212) 953-2497. For reprint orders in limited quantities for educational distribution, please contact Rita Houston, 515 N State St, Chicago, IL 60610. Phone: (312) 464-2512. Fax: (312) 464-5835.

PERMISSIONS—Contact Laslo Hunyady, Permissions Assistant, 515 N State St, Chicago, IL 60610. Phone: (312) 464-2513.

ADVERTISING PRINCIPLES—Each advertisement in this issue has been reviewed and complies with the principles governing advertising in AMA scientific publications. A copy of these principles is available on request. The appearance of advertising in AMA publications is not an AMA guarantee or endorsement of the product or the claims made for the product by the manufacturer.

A MORE COMPLETE
OTC ANALGESIC.



ALEVE IS THE ONLY OTC ANALGESIC WITH:

THE **ENDURANCE**
OF 8–12 HOUR DOSING.

THE **TOLERABILITY**
THAT'S COMPARABLE TO IBUPROFEN
AND EVEN ACETAMINOPHEN.

AND THE **SPEED**
AND ACTIVITY OF NAPROXEN SODIUM.

INSTEAD OF ADVIL OR TYLENOL
RECOMMEND

ALEVE®
NAPROXEN SODIUM 220 MG
PAIN RELIEVER/FEVER REDUCER

A MORE COMPLETE
OTC ANALGESIC.

ARCHIVES OF FAMILY MEDICINE

VOL 4 NO. 5, MAY 1995

American Medical Association
Physicians dedicated to the health of America

in other conditions, pseudoxanthoma elasticum is the most frequent systemic association.[2] Angioid streaks eventually appear in the majority of patients with pseudoxanthoma elasticum.

The pattern of yellow dots at the level of the retinal pigment epithelium has been called "peau d'orange" and is thought to be a precursor of angioid streaks.[3] That such a dramatic fundus appearance causes little or no disturbance of the fluorescein angiogram is surprising.

Patients with angioid streaks are known to be susceptible to subretinal hemorrhage following even mild trauma. Our patient's condition suggests that this risk exists prior to the development of clinically evident angioid streaks.

This study was supported by grant EY01730 from the National Eye Institute, Rockville, Md (Dr Kalina), and by an award from Research to Prevent Blindness Inc, New York, NY (Dr Kalina).

Selected from Arch Ophthalmol. *1994;112:1622-1623. Photo Essay.*

REFERENCES

1. Clarkson JG, Altman RD. Angioid streaks. *Surv Ophthalmol.* 1982;26:235-246.
2. Connor PJ Jr, Juergens JL, Perry HO, et al. Pseudoxanthoma elasticum and angioid streaks: a review of 106 cases. *Am J Med.* 1961;30:537-543.
3. Krill AE, Klein BA, Archer DB. Precursors of angioid streaks. *Am J Ophthalmol.* 1973;76:875-879.

but with older people being the fastest growing segment of the population, we need to get to the well-accepted stage quickly or go broke paying for nursing homes.

Two pieces that appeared by coincidence the same day in our local newspaper explain why I think everyone should know about adult day centers. The first was an article about a tragedy in Pittsburgh, Pa, in which a man who felt he was alone in caring for his wife with Alzheimer's disease shot her and then killed himself. The second was a short letter to the editor by a thankful husband whose wife was enrolled in an adult day center, and he described how much it meant to both of them. A day center can't transform total despair into contentment, but I can't help wondering whether the first man had access to one.

If you think I need a day center, please enroll me. If I object, look at it the same way you did when you left Jason and Dana at child day care the first time. Like them, I might make a fuss, but by the time you're playing your first set of tennis, I'll be too busy to notice you're gone. At night I can have some pasta while watching a tape of an old golf tournament I've seen a hundred times before and still be in suspense at the outcome. What nursing home can match that?

Love,
Burton

PS. It's easy to find the nearest adult day center. You can call our local senior citizen center, the local area agency on aging, the state Department of Aging Services, or the National Institute on Adult Daycare in Washington, DC, at (202) 479-1200.

Burton V. Reifler, MD, MPH
Bowman Gray School of Medicine
Winston-Salem, NC

Dr Reifler is director of Partners in Caregiving, a National Demonstration Program supported by The Robert Wood Johnson Foundation, New York, NY.

Reprint requests to Department of Psychiatry, Bowman Gray School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1087 (Dr Reifler).

AQ Comfort and QD Convenience...

Just One Nasal Steroid Has Both:

NEW FLONASE™

(fluticasone propionate)

- A first-line therapy for management of seasonal and perennial allergic rhinitis in patients 12 years and older – not indicated for nonallergic rhinitis.
- Relief of nasal symptoms may begin within 12 hours.
- Maximum benefit may take several days. Onset of action and degree of relief may vary in individual patients.
- Effectiveness depends on regular use.
- Side effects occurring at >1% (causal relationship possible) included epistaxis and nasal burning (3% to 6%) and nasal irritation, headache, and pharyngitis (1% to 3%).

Please consult Brief Summary of Prescribing Information on adjacent page.

Focused Relief for Allergic Rhinitis...

NEW FLONASE™ NASAL SPRAY, 0.05%

(fluticasone propionate) QD AQ

The Aqueous/Once-a-Day ANTI-RHINITIC™

Flonase™
(fluticasone propionate) Nasal Spray, 0.05% w/w

BRIEF SUMMARY

SHAKE GENTLY BEFORE USE.

For Intranasal Use Only.

The following is a brief summary only. Before prescribing, see complete prescribing information in Flonase™ Nasal Spray product labeling.

CONTRAINDICATIONS: Flonase™ Nasal Spray is contraindicated in patients with a hypersensitivity to any of its ingredients.

WARNINGS: The replacement of a systemic glucocorticoid with a topical glucocorticoid can be accompanied by signs of adrenal insufficiency, and in addition some patients may experience symptoms of withdrawal, e.g., joint and/or muscular pain, lassitude, and depression. Patients previously treated for prolonged periods with systemic glucocorticoids and transferred to topical glucocorticoids should be carefully monitored for acute adrenal insufficiency in response to stress. In those patients who have asthma or other clinical conditions requiring long-term systemic glucocorticoid treatment, too rapid a decrease in systemic glucocorticoids may cause a severe exacerbation of their symptoms.

The use of Flonase™ Nasal Spray with alternate-day systemic prednisone could increase the likelihood of hypothalamic-pituitary-adrenal (HPA) suppression compared with a therapeutic dose of either one alone. Therefore, Flonase Nasal Spray should be used with caution in patients already receiving alternate-day prednisone treatment for any disease. In addition, the concomitant use of Flonase Nasal Spray with other inhaled glucocorticoids could increase the risk of signs or symptoms of hypercorticism and/or suppression of the HPA axis.

Patients who are on immunosuppressant drugs are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in patients on immunosuppressant doses of corticosteroids. In such patients who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information). If chickenpox develops, treatment with antiviral agents may be considered.

PRECAUTIONS:

General: Rarely, immediate hypersensitivity reactions or contact dermatitis may occur after the intranasal administration of fluticasone propionate. Rare instances of wheezing, nasal septum perforation, cataracts, glaucoma, and increased intraocular pressure have been reported following the intranasal application of glucocorticoids.

Use of excessive doses of glucocorticoids may lead to signs or symptoms of hypercorticism, suppression of HPA function, and/or suppression of growth in children or teenagers. Knemometry studies in asthmatic children on orally inhaled glucocorticoids showed inhibitory effects on short-term growth rate. The relationship between short-term changes in lower leg growth and long-term effects on growth is unclear at this time. Physicians should closely follow the growth of adolescents taking glucocorticoids, by any route, and weigh the benefits of glucocorticoid therapy against the possibility of growth suppression if an adolescent's growth appears slowed.

Although systemic effects have been minimal with recommended doses of Flonase™ Nasal Spray, potential risk increases with larger doses. Therefore, larger than recommended doses of Flonase Nasal Spray should be avoided.

When used at larger doses, systemic glucocorticoid effects such as hypercorticism and adrenal suppression may appear. If such changes occur, the dosage of Flonase Nasal Spray should be discontinued slowly consistent with accepted procedures for discontinuing oral glucocorticoid therapy.

In clinical studies with fluticasone propionate administered intranasally, the development of localized infections of the nose and pharynx with *Candida albicans* has occurred only rarely. When such an infection develops, it may require treatment with appropriate local therapy and discontinuation of treatment with Flonase Nasal Spray. Patients using Flonase Nasal Spray over several months or longer should be examined periodically for evidence of *Candida* infection or other signs of adverse effects on the nasal mucosa.

Flonase Nasal Spray should be used with caution, if at all, in patients with active or quiescent tuberculous infections; untreated fungal, bacterial, or systemic viral infections; or ocular herpes simplex.

Because of the inhibitory effect of glucocorticoids on wound healing, patients who have experienced recent nasal septal ulcers, nasal surgery, or nasal trauma should not use a nasal glucocorticoid until healing has occurred.

Information for Patients: Patients being treated with Flonase Nasal Spray should receive the following information and instructions. This information is intended to aid them in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Patients should be warned to avoid exposure to chickenpox or measles and, if exposed, to consult their physician without delay.

Patients should use Flonase Nasal Spray at regular intervals as directed since its effectiveness depends on its regular use. A decrease in nasal symptoms may occur as soon as 12 hours after starting therapy with Flonase Nasal Spray. Results in several clinical trials indicate statistically significant improvement within the first day or two of treatment; however, the full benefit of Flonase Nasal Spray may not be achieved until treatment has been administered for several days. The patient should not increase the prescribed dosage but should contact the physician if symptoms do not improve or if the condition worsens. For the proper use of the nasal spray and to attain maximum improvement, the patient should read and follow carefully the patient's instructions accompanying the product.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Fluticasone propionate demonstrated no tumorigenic potential in studies of oral doses up to 1.0 mg/kg (3 mg/m^2 as calculated on a surface area basis) for 78 weeks in the mouse or inhalation of up to 57 mcg/kg (336 mcg/m^2) for 104 weeks in the rat.

Fluticasone propionate did not induce gene mutation in prokaryotic or eukaryotic cells *in vitro*. No significant clastogenic effect was seen in cultured human peripheral lymphocytes *in vitro* or in the mouse micronucleus test when administered at high doses by the oral or subcutaneous routes. Furthermore, the compound did not delay erythroblast division in bone marrow.

No evidence of impairment of fertility was observed in reproductive studies conducted in rats dosed subcutaneously with doses up to 50 mcg/kg (295 mcg/m^2) in males and females. However, prostate weight was significantly reduced in rats.

Pregnancy: ***Teratogenic Effects: Pregnancy Category C:*** Subcutaneous studies in the mouse and rat at 45 and 100 mcg/kg, respectively (135 and 590 mcg/m^2, respectively, as calculated on a surface area basis), revealed fetal toxicity characteristic of potent glucocorticoid compounds, including embryonic growth retardation, omphalocele, cleft palate, and retarded cranial ossification.

In the rabbit, fetal weight reduction and cleft palate were observed following subcutaneous doses of 4 mcg/kg (48 mcg/m^2).

However, following oral administration of up to 300 mcg/kg (3.6 mg/m^2) of fluticasone propionate to the rabbit, there were no maternal effects nor increased incidence of external, visceral, or skeletal fetal defects. No fluticasone propionate was detected in the plasma in this study, consistent with the established low bioavailability following oral administration (see CLINICAL PHARMACOLOGY section of the full prescribing information).

Less than 0.008% of the dose crosses the placenta following oral administration to rats (100 mcg/kg, 590 mcg/m^2) or rabbits (300 mcg/kg, 3.6 mg/m^2).

There are no adequate and well-controlled studies in pregnant women. Fluticasone propionate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Experience with oral glucocorticoids since their introduction in pharmacologic, as opposed to physiologic, doses suggests that rodents are more prone to teratogenic effects from glucocorticoids than humans. In addition, because there is a natural increase in glucocorticoid production during pregnancy, most women will require a lower exogenous glucocorticoid dose and many will not need glucocorticoid treatment during pregnancy.

Nursing Mothers: It is not known whether fluticasone propionate is excreted in human breast milk. Subcutaneous administration of tritiated drug to lactating rats (10 mcg/kg, 59 mcg/m^2) resulted in measurable radioactivity in both plasma and milk. Because other glucocorticoids are excreted in human milk, caution should be exercised when Flonase Nasal Spray is administered to a nursing woman.

Pediatric Use: The safety and effectiveness of Flonase Nasal Spray in children below 12 years of age have not been established. Oral glucocorticoids have been shown to cause growth suppression in children and teenagers with extended use. If a child or teenager on any glucocorticoid appears to have growth suppression, the possibility that they are particularly sensitive to this effect of glucocorticoids should be considered (see PRECAUTIONS).

Geriatric Use: A limited number of patients above 60 years of age (n=132) have been treated with Flonase Nasal Spray in US and non-US clinical trials. While the number of patients is too small to permit separate analysis of efficacy and safety, the adverse reactions reported in this population were similar to those reported by younger patients.

ADVERSE REACTIONS: In controlled US studies, 2,427 patients received treatment with intranasal fluticasone propionate. In general, adverse reactions in clinical studies have been primarily associated with irritation of the nasal mucous membranes, and the adverse reactions were reported with approximately the same frequency by patients treated with the vehicle itself. The complaints did not usually interfere with treatment. Less than 2% of patients in clinical trials discontinued because of adverse events; this rate was similar for vehicle and active comparators.

Systemic glucocorticoid side effects were not reported during controlled clinical studies up to 6 months duration with Flonase™ Nasal Spray. If recommended doses are exceeded, however, or if individuals are particularly sensitive or if in conjunction with systemically administered glucocorticoids, symptoms of hypercorticism, e.g., Cushing's syndrome, could occur.

The following incidence of common adverse reactions is based upon seven controlled clinical trials in which 536 patients (57 girls and 108 boys aged 4 to 11 years, 137 female and 234 male adolescents and adults) were treated with Flonase Nasal Spray 200 mcg once daily over 2 to 4 weeks and two controlled clinical trials in which 246 patients (119 female and 127 male adolescents and adults) were treated with Flonase Nasal Spray 200 mcg once daily over 6 months.

Incidence Greater than 1% (Causal Relationship Possible): ***Respiratory:*** Epistaxis, nasal burning (incidence 3% to 6%); blood in nasal mucus, pharyngitis, nasal irritation (incidence 1% to 3%).

Neurological: Headache (incidence 1% to 3%).

Incidence Less than 1% (Causal Relationship Possible): ***Respiratory:*** Sneezing, runny nose, nasal dryness, sinusitis, nasal congestion, bronchitis, nasal ulcer, nasal septum excoriation.

Neurological: Dizziness.

Special Senses: Eye disorder, unpleasant taste.

Digestive: Nausea and vomiting, xerostomia.

Skin and Appendages: Urticaria.

OVERDOSAGE: There are no data available on the effects of acute or chronic overdosage with Flonase™ Nasal Spray. Intranasal administration of 2 mg (10 times the recommended dose) of fluticasone propionate twice daily for 7 days to healthy human volunteers was well tolerated. Single oral doses up to 16 mg have been studied in human volunteers with no acute toxic effects reported. Repeat oral doses up to 80 mg daily for 10 days in volunteers and repeat oral doses up to 10 mg daily for 14 days in patients were well tolerated. Adverse reactions were of mild or moderate severity, and incidences were similar in active and placebo treatment groups. Acute overdosage with this dosage form is unlikely since one bottle of Flonase Nasal Spray contains approximately 8 mg of fluticasone propionate. Chronic overdosage may result in signs/symptoms of hypercorticism (see PRECAUTIONS).

Allen & Hanburys
DIVISION OF GLAXO INC.
Research Triangle Park, NC 27709

October 1994
RL-148
OM.BS.A



Allen & Hanburys
DIVISION OF GLAXO INC.
a world leader in respiratory care
Research Triangle Park, NC 27709

FLN141R0 Printed in USA January 1995

If the U.S. Senate Can Deliver Health Care Liability Reform, Maureen O'Regan Can Deliver Babies Anywhere.

Meet Dr. Maureen O'Regan.

She's an obstetrician in northern Virginia, within sight of the nation's Capitol.

She delivers babies in Virginia where there's a limit on health care liability awards.

Just across the Potomac River, in Washington, D.C., there is no limit, and malpractice insurance costs at least $68,000 – more than twice the cost in Virginia.

Dr. O'Regan would like to deliver babies in Washington, but the cost is too high and the risk is too great.

She's not alone. One out of eight obstetrician/ gynecologists nationally no longer delivers babies. Other doctors all across the country struggle with the same dilemma.

Without liability caps, huge amounts of money are spent on defensive medicine. Physicians must order more procedures and tests than the patient really needs. The trust between patient and physician is threatened.

Congress can fix this. The U.S. House of Representatives has already passed a bill that would set a $250,000 cap on noneconomic damages. Now it's up to the U.S. Senate.

Contact your U.S. Senators **now**. Tell them to vote for Health Care Liability Reform.

And let Dr. O'Regan deliver babies wherever she's needed.

*Write **both** U.S. Senators c/o U.S. Senate, Washington, D.C. 20510. Or call their offices at (202) 224-3121.*

American Medical Association

Physicians dedicated to the health of America

American Medical Association's

15th Annual Health Reporting Conference

Sharpen your medical communicating skills at the AMA's 15th Annual Health Reporting Conference, Thursday, June 22 through Sunday, June 25, 1995 at The Sutton Place, Newport Beach, California.

This is a unique conference designed for medical reporters, physician broadcasters and medical spokespeople. The conference features skills development in broadcast writing, interviewing, editing and production, plus opportunities to have your on-air work critiqued by experts. Network with the pros, get valuable tips on breaking into the business, new technology and dealing with the issues confronting medical communicators today.

Faculty includes experienced physicians broadcasters, network producers, broadcast consultants, writers, editors, media trainers and professional speakers' trainers.

Registration Fees*:	Until May 1	May 1 & beyond**
AMA member	$650	$750
Nonmember	$850	$950
Students/Residents	$300	$350
Individual Coaching Sessions:		
AMA Member	$100	***
Nonmember	$125	***

Course tracks are offered in Speakers Training, Broadcasting (Introductory and Advanced levels) and Medical Communications Technology. Electives are open to all participants.

Fee includes Welcome Reception, continental breakfasts, luncheons, video and audiotapes, workshops and materials.

To obtain registration materials and/or more information, complete and return this form by fax to **312 464-5843** or mail to address below, or call **312 464-5852**.

* No increase over '94

** Registration will be accepted only on a space available basis after May 1, 1995 cut-off date.

*** Not available after May 1, 1995.



Funding provided by educational grants from Bristol-Myers Squibb, Ciba Pharmaceuticals, Glaxo and Ortho-McNeil.

Newport Beach, California
June 22-25, 1995

Jill Stewart, Conference Director
Health Reporting Conference
American Medical Association
515 North State Street
Chicago, Illinois 60610

Name _____ Specialty _____

Address _____

City _____ State _____ Zip _____

Phone number (office) _____ (home) _____

American Medical Association

Physicians dedicated to the health of America

lence. In: Straus MA, Gelles RJ, eds. *Physical Violence in American Families: Risk Factors and Adaptations to Violence in 8,145 Families.* New Brunswick, NJ: Transaction Publishers; 1990:507-526.
23. Rosner B. *Fundamentals of Biostatistics.* 3rd ed. Boston, Mass: PWS-Kent Publishing Co; 1990.
24. Norusis MJ. *SPSS for Windows: Base System User's Guide.* Release 5.0 ed. Chicago, Ill: SPSS Inc; 1992.
25. Gin NE, Rucker L, Frayne S, Cygan R, Hubbell FA. Prevalence of domestic violence among patients in three ambulatory care internal medicine clinics. *J Gen Intern Med.* 1991;6:317-322.
26. Feld SL, Straus MA. Escalation and desistance from wife assault in marriage. In: Straus MA, Gelles RJ, eds. *Physical Violence in American Families: Risk Factors and Adaptations to Violence in 8,145 Families.* New Brunswick, NJ: Transaction Publishers; 1990:489-498.
27. Suitor JJ, Pillemar K, Straus MA. Marital violence in a life course perspective. In: Straus MA, Gelles RJ, eds. *Physical Violence in American Families: Risk Factors and Adaptations to Violence in 8,145 Families.* New Brunswick, NJ: Transaction Publishers; 1990:305-317.
28. Hanneke CR, Shields NM, McCall GJ. Assessing the prevalence of marital rape. *J Interpersonal Violence.* 1986;1:350-362.
29. Browne A. *When Battered Women Kill.* New York, NY: Free Press; 1987.
30. Campbell JC. Women's responses to sexual abuse in intimate relationships. *Health Care Women Int.* 1989;10:335-346.
31. Rosenberg ML, Mercy JA. Homicide: epidemiologic analysis at the national level. *Bull N Y Acad Med.* 1986;62:376-399.
32. Sims DW, Bivins BA, Obzid FN, Horst HM, Sorenson VJ, Fath JJ. Urban trauma: a chronic recurrent disease. *J Trauma.* 1989;7:940-947.
33. Okun L. *Woman Abuse: Facts Replacing Myths.* Albany: State University of New York Press; 1986.
34. McIntyre D. Domestic violence: a case of the disappearing victim? *Aust J Fam Ther.* 1984;5:249-258.
35. Straus MA, Gelles RJ. Societal change and change in family violence from 1975-1985. In: Straus MA, Gelles RJ, eds. *Physical Violence in American Families: Risk Factors and Adaptations to Violence in 8,145 Families.* New Brunswick, NJ: Transaction Publishers; 1990:113-131.
36. Grasmick HG, Blackwell BS, Bursick RJ Jr, Mitchell S. Changes in perceived threats of shame, embarassment, and legal sanctions for interpersonal violence, 1982-1992. *Violence Victims.* 1993;8:313-325.
37. Sackett DL. Bias in analytic research. *J Chronic Dis.* 1979;32:51-63.
38. Dowell M. Sexual harassment in academia: legal and administrative challenges. *J Nurs Educ.* 1992;31:5-9.
39. Baldwin DC, Daugherty SR, Eckenfels EJ. Student perceptions of mistreatment and harassment during medical school: a survey of ten United States schools. *West J Med.* 1991;155:140-145.
40. Petrocelli W, Repa BK. *Sexual Harassment on the Job.* Berkeley, Calif: Nolo Press; 1992.

Give allergic noses relief for itchy eyes due to seasonal allergic conjunctivitis.

When seasonal allergies strike, it's not just the nose they ambush. The eyes are fair game, too. In fact, 8 out of 10 patients with allergic noses also suffer from itchy eyes[1] due to seasonal allergic conjunctivitis. Stop the itch with ACULAR® Solution.

In a recent survey (n=272), the vast majority of responding patients confirmed that ACULAR® stopped their ocular itching quickly and effectively.[2] Plus, ACULAR® has a favorable safety profile. There are no steroid-like side effects that can alter intraocular pressure, and no decongestant-like side effects, i.e., no risk to patients with narrow chamber angles.

So help rescue eyes from itching with ACULAR,® the #1 prescribed ophthalmic preparation[3] for the #1 patient complaint of seasonal allergic conjunctivitis — ocular itch. Because annoying antigens prey on more than just the nose.

The most frequently reported adverse events have been transient stinging and burning on instillation (approximately 40%). Not for use while wearing soft contact lenses.

STOPS THE ITCH
ACULAR®
(ketorolac tromethamine) 0.5%
Sterile Ophthalmic Solution

ALLERGAN

Irvine, CA 92715

FISONS Pharmaceuticals
Fisons Corporation
Rochester, NY 14623 U.S.A.

Please see adjacent page for prescribing information.



When it comes to accuracy, St. Anthony's is the ICD-9-CM of choice.

St. Anthony's, one of the most respected names in *ICD-9-CM* coding, has combined Volumes 1 and 2 of the *ICD-9-CM* into easy-to-use reference books. Choose the full-sized color-coded, or the compact black and white to help increase your coding efficiency and accuracy.

St. Anthony's *ICD-9-CM 1995 Code Book*

This 6 x 9" softbound edition of the *ICD-9-CM* is for the coder on the move. Whether at home, at the office, or in the classroom, this reference will prove invaluable. Printed in straightforward black and white, with new FasTabs, and special symbols that flag the need for fifth digits, this convenient *ICD-9-CM* is an essential tool for precise coding. The right choice for the value-conscious coder.

St. Anthony's *ICD-9-CM 1995 Code Book*
Order #: OP051995NQ
AMA member price: $29.95
Nonmember price: $39.95

St. Anthony's *Color-Coded ICD-9-CM 1995*

With this softbound reference, "color" is the code word for accuracy. St. Anthony's highlights restricted codes, unspecified codes, and manifestation codes, so you can highlight precision. With the help of new FasTabs, special symbols that alert you to fifth digits, and clarified HCFA rules and coding examples, your coding can become error-free.

St. Anthony's *Color-Coded ICD-9-CM 1995*
Order #: OP056595NQ
AMA member price: $47.95
Nonmember price: $59.95

To order, call toll free 800 621-8335
MasterCard, VISA, American Express, and Optima accepted.
State sales taxes and shipping/handling charges apply.

Order today!

American Medical Association
Physicians dedicated to the health of America

Reader Information

ONLINE SERVICES

Ovid Technologies, Inc.
333 Seventh Avenue, New York, NY 10001
Phone: 212-563-3006; Fax: 212-563-3784
Full-text articles from JAMA

Dialog Information Services, Inc.
3460 Hillview Avenue, PO Box 10010, Palo Alto, CA 94303
Phone: 800-3-DIALOG; Fax: 415-858-7069
Full-text articles from JAMA and the Archives journals

Information Access Company
362 Lakeside Drive, Foster City, CA 94404
Phone: 800-227-8431; Fax: 415-378-5369
Full-text articles from JAMA, the Archives journals and American Medical News

Note: AMA publications are no longer available through Nexis/Lexis Research Services.

ALERT SERVICE

Available July 1, 1995

Individual Inc.
8 New England Executive Park West, Burlington, MA 01803
Phone: 800-866-2266; Fax: 617-273-6060
Provides abstracts only for current issues of JAMA and the Archives by fax

DOCUMENT DELIVERY

Copies of complete articles from JAMA and the Archives journals

Genuine Article/Institute for Scientific Information
3501 Market Street, Philadelphia, PA 19104
Phone: 215-386-0100, ext. 1140-1145; Fax: 215-386-4343
and 215-222-0840; Internet: TGA @ ISINET.COM

Uncover Company
3801 E. Florida, Suite 200, Denver, CO 80210
Phone: 303-758-3030; Fax: 303-758-5946; Internet: database.carl.org

UMI InfoStore
500 Sansome Street, Suite 400, San Francisco, CA 94111
Phone: 800-248-0360; Fax: 415-433-0100

CD/ROM

Appleton and Lange
25 Van Zant Avenue, PO Box 5630, Norwalk, CT 06856-5630
Phone: 203-838-4400; Fax: 203-857-4148
JAMA available from 1986 through 1993 in full text on a single disc

Information Access Company
362 Lakeside Drive, Foster City, CA 94404
Phone: 800-227-8431; Fax: 415-378-5369
Full text of JAMA and AMNews updated monthly in a rolling, 3-year format

American Psychiatric Press
1400 K Street, NW, Washington, DC 20005
Phone: 202-682-6268; Fax: 202-789-2648
Full text of Archives of General Psychiatry updated quarterly

MICROFILM

UMI
300 North Zeeb Road, Ann Arbor, MI 48106-1346
Phone: 313-761-4700; Fax: 313-973-2088
JAMA and the Archives journals available

SUBSCRIBER SERVICES

For information regarding subscriptions, change of address, missing issues, or purchasing back issues, please contact Subscriber Services Center, PO Box 10945, Chicago, IL 60610, at the numbers below. The Center's hours are between 8:30 am and 4:30 pm CST.

JAMA BOUND VOLUMES

Preserve a complete year of JAMA with an archival, bound volume set. Issues are printed on acid-free paper and include full-color covers. Each compact volume holds six months of issues and is just 2 1/4 inches thick for easy handling. Bound volume sets are available beginning with 1994. See information below to order. Please specify 1994 or 1995 subscription year when ordering.

SINGLE COPY SALES

Issues published in the last two years are available for purchase, subject to availability. Single copy rates for delivery in the US are: $11 per copy of JAMA; $16 per copy of the Archives journals; and $8 per copy of American Medical News. Prepayment is required. Issues can be ordered by phone, mail, or fax through Subscriber Services at the numbers below.

REPRINTS

Authorized reprints may be purchased in quantities of 300 or more. For smaller quantities, back issues may be purchased at the single copy rate. For prices and ordering information, contact the Reprints Coordinator, PO Box 10945, Chicago, IL 60610. Phone: 312-464-2521.

PHYSICIAN RECRUITMENT ADVERTISING

JAMA physician recruitment advertising rates are $4.25 per word, per issue (bold type is $4.65 per word, per issue), with a miniumum of 20 words. Blind Box Service is available at an additional cost of $20 per issue. For further information and rates on physician recruitment advertising and network buys for all AMA publications, contact an AMA Physician Recruitment Representative at 312-464-2475/2490/2491/4485; Fax: 312-464-5909.

SUBSCRIBE TO AMA PUBLICATIONS

For information on any of these AMA publications, or to place an order, contact Subscriber Services at 800-AMA-2350 (Fax: 312-464-5831). A surcharge for expedited airmail delivery will be added for all orders outside the US. Mail your order to: Subscriber Services Center, PO Box 10945, Chicago, IL 60610.

1995 Subscription Rates	***Individual***	***Institution***
JAMA: The Journal of the American Medical Association (48 issues)	$120	$140
Archives of Dermatology (12 issues)	$135	$150
Archives of Family Medicine (12 issues)	$ 95	$105
Archives of General Psychiatry (12 issues)	$ 95	$110
Archives of Internal Medicine (22 issues)	$115	$135
Archives of Neurology (12 issues)	$145	$175
Archives of Ophthalmology (12 issues)	$110	$125
Archives of Otolaryngology-Head & Neck Surgery (12 issues)	$125	$145
Archives of Pediatrics & Adolescent Medicine (12 issues)	$100	$125
Archives of Surgery (12 issues)	$100	$115
American Medical News (48 issues)	$ 99	$139
New! JAMA Bound Volumes (2 archival volumes)	Set $ 95	$ 95

PHONE: 312-670-SUBS [670-7827]
FAX: 312-464-5831

For clarity and simplicity, coders choose Medicode's HCPCS.



Those who work with *HCPCS* know Medicode has the friendliest book on the market. It's easy to work with and the one many coders feel comfortable using.

Medicode *HCPCS 1995*

The Medicode *HCPCS* is better than ever. It's an essential tool for any medical office. This easy-to-use, spiral-bound, 8 1/2 x 11" edition includes:

- a cross-referencing of generic drugs with the most frequently prescribed brand-name equivalents
- links between deleted *HCPCS* codes and active codes
- an expanded index of all entries

It's an effective and valuable reference for coding all your durable medical equipment, drugs, and select medical services.

Medicode *HCPCS 1995*
Order #: OP057395NQ
AMA member price: $29.95
Nonmember price: $34.95

To order, call toll free 800 621-8335
MasterCard, VISA, American Express, and Optima accepted.
State sales taxes and shipping/handling charges apply.

Order today!

American Medical Association
Physicians dedicated to the health of America

AQ Comfort and QD Convenience...

Just One Nasal Steroid Has Both:

NEW FLONASE™

(fluticasone propionate)

- A first-line therapy for management of seasonal and perennial allergic rhinitis in patients 12 years and older – not indicated for nonallergic rhinitis.
- Relief of nasal symptoms may begin within 12 hours.
- Maximum benefit may take several days. Onset of action and degree of relief may vary in individual patients.

- Effectiveness depends on regular use.
- Side effects occurring at >1% (causal relationship possible) included epistaxis and nasal burning (3% to 6%) and nasal irritation, headache, and pharyngitis (1% to 3%).

Please consult Brief Summary of Prescribing Information on adjacent page.

Focused Relief for Allergic Rhinitis...

NEW FLONASE™ NASAL SPRAY, 0.05%

(fluticasone propionate) QD AQ

The Aqueous/Once-a-Day ANTI-RHINITIC™

Flonase™
(fluticasone propionate)
Nasal Spray, 0.05% w/w

BRIEF SUMMARY

SHAKE GENTLY BEFORE USE.

For Intranasal Use Only.

The following is a brief summary only. Before prescribing, see complete prescribing information in Flonase™ Nasal Spray product labeling.

CONTRAINDICATIONS: Flonase™ Nasal Spray is contraindicated in patients with a hypersensitivity to any of its ingredients.

WARNINGS: The replacement of a systemic glucocorticoid with a topical glucocorticoid can be accompanied by signs of adrenal insufficiency, and in addition some patients may experience symptoms of withdrawal, e.g., joint and/or muscular pain, lassitude, and depression. Patients previously treated for prolonged periods with systemic glucocorticoids and transferred to topical glucocorticoids should be carefully monitored for acute adrenal insufficiency in response to stress. In those patients who have asthma or other clinical conditions requiring long-term systemic glucocorticoid treatment, too rapid a decrease in systemic glucocorticoids may cause a severe exacerbation of their symptoms.

The use of Flonase™ Nasal Spray with alternate-day systemic prednisone could increase the likelihood of hypothalamic-pituitary-adrenal (HPA) suppression compared with a therapeutic dose of either one alone. Therefore, Flonase Nasal Spray should be used with caution in patients already receiving alternate-day prednisone treatment for any disease. In addition, the concomitant use of Flonase Nasal Spray with other inhaled glucocorticoids could increase the risk of signs or symptoms of hypercorticism and/or suppression of the HPA axis.

Patients who are on immunosuppressant drugs are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in patients on immunosuppressant doses of corticosteroids. In such patients who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information). If chickenpox develops, treatment with antiviral agents may be considered.

PRECAUTIONS:

General: Rarely, immediate hypersensitivity reactions or contact dermatitis may occur after the intranasal administration of fluticasone propionate. Rare instances of wheezing, nasal septum perforation, cataracts, glaucoma, and increased intraocular pressure have been reported following the intranasal application of glucocorticoids.

Use of excessive doses of glucocorticoids may lead to signs or symptoms of hypercorticism, suppression of HPA function, and/or suppression of growth in children or teenagers. Knemometry studies in asthmatic children on orally inhaled glucocorticoids showed inhibitory effects on short-term growth rate. The relationship between short-term changes in lower leg growth and long-term effects on growth is unclear at this time. Physicians should closely follow the growth of adolescents taking glucocorticoids, by any route, and weigh the benefits of glucocorticoid therapy against the possibility of growth suppression if an adolescent's growth appears slowed.

Although systemic effects have been minimal with recommended doses of Flonase™ Nasal Spray, potential risk increases with larger doses. Therefore, larger than recommended doses of Flonase Nasal Spray should be avoided.

When used at larger doses, systemic glucocorticoid effects such as hypercorticism and adrenal suppression may appear. If such changes occur, the dosage of Flonase Nasal Spray should be discontinued slowly consistent with accepted procedures for discontinuing oral glucocorticoid therapy.

In clinical studies with fluticasone propionate administered intranasally, the development of localized infections of the nose and pharynx with *Candida albicans* has occurred only rarely. When such an infection develops, it may require treatment with appropriate local therapy and discontinuation of treatment with Flonase Nasal Spray. Patients using Flonase Nasal Spray over several months or longer should be examined periodically for evidence of *Candida* infection or other signs of adverse effects on the nasal mucosa.

Flonase Nasal Spray should be used with caution, if at all, in patients with active or quiescent tuberculous infections; untreated fungal, bacterial, or systemic viral infections; or ocular herpes simplex.

Because of the inhibitory effect of glucocorticoids on wound healing, patients who have experienced recent nasal septal ulcers, nasal surgery, or nasal trauma should not use a nasal glucocorticoid until healing has occurred.

Information for Patients: Patients being treated with Flonase Nasal Spray should receive the following information and instructions. This information is intended to aid them in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Patients should be warned to avoid exposure to chickenpox or measles and, if exposed, to consult their physician without delay.

Patients should use Flonase Nasal Spray at regular intervals as directed since its effectiveness depends on its regular use. A decrease in nasal symptoms may occur as soon as 12 hours after starting therapy with Flonase Nasal Spray. Results in several clinical trials indicate statistically significant improvement within the first day or two of treatment; however, the full benefit of Flonase Nasal Spray may not be achieved until treatment has been administered for several days. The patient should not increase the prescribed dosage but should contact the physician if symptoms do not improve or if the condition worsens. For the proper use of the nasal spray and to attain maximum improvement, the patient should read and follow carefully the patient's instructions accompanying the product.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Fluticasone propionate demonstrated no tumorigenic potential in studies of oral doses up to 1.0 mg/kg (3 mg/m^2 as calculated on a surface area basis) for 78 weeks in the mouse or inhalation of up to 57 mcg/kg (336 mcg/m^2) for 104 weeks in the rat.

Fluticasone propionate did not induce gene mutation in prokaryotic or eukaryotic cells *in vitro*. No significant clastogenic effect was seen in cultured human peripheral lymphocytes *in vitro* or in the mouse micronucleus test when administered at high doses by the oral or subcutaneous routes. Furthermore, the compound did not delay erythroblast division in bone marrow.

No evidence of impairment of fertility was observed in reproductive studies conducted in rats dosed subcutaneously with doses up to 50 mcg/kg (295 mcg/m^2) in males and females. However, prostate weight was significantly reduced in rats.

Pregnancy: ***Teratogenic Effects: Pregnancy Category C:*** Subcutaneous studies in the mouse and rat at 45 and 100 mcg/kg, respectively (135 and 590 mcg/m^2, respectively, as calculated on a surface area basis), revealed fetal toxicity characteristic of potent glucocorticoid compounds, including embryonic growth retardation, omphalocele, cleft palate, and retarded cranial ossification.

In the rabbit, fetal weight reduction and cleft palate were observed following subcutaneous doses of 4 mcg/kg (48 mcg/m^2).

However, following oral administration of up to 300 mcg/kg (3.6 mg/m^2) of fluticasone propionate to the rabbit, there were no maternal effects nor increased incidence of external, visceral, or skeletal fetal defects. No fluticasone propionate was detected in the plasma in this study, consistent with the established low bioavailability following oral administration (see CLINICAL PHARMACOLOGY section of the full prescribing information).

Less than 0.008% of the dose crosses the placenta following oral administration to rats (100 mcg/kg, 590 mcg/m^2) or rabbits (300 mcg/kg, 3.6 mg/m^2).

There are no adequate and well-controlled studies in pregnant women. Fluticasone propionate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Experience with oral glucocorticoids since their introduction in pharmacologic, as opposed to physiologic, doses suggests that rodents are more prone to teratogenic effects from glucocorticoids than humans. In addition, because there is a natural increase in glucocorticoid production during pregnancy, most women will require a lower exogenous glucocorticoid dose and many will not need glucocorticoid treatment during pregnancy.

Nursing Mothers: It is not known whether fluticasone propionate is excreted in human breast milk. Subcutaneous administration of tritiated drug to lactating rats (10 mcg/kg, 59 mcg/m^2) resulted in measurable radioactivity in both plasma and milk. Because other glucocorticoids are excreted in human milk, caution should be exercised when Flonase Nasal Spray is administered to a nursing woman.

Pediatric Use: The safety and effectiveness of Flonase Nasal Spray in children below 12 years of age have not been established. Oral glucocorticoids have been shown to cause growth suppression in children and teenagers with extended use. If a child or teenager on any glucocorticoid appears to have growth suppression, the possibility that they are particularly sensitive to this effect of glucocorticoids should be considered (see PRECAUTIONS).

Geriatric Use: A limited number of patients above 60 years of age (n=132) have been treated with Flonase Nasal Spray in US and non-US clinical trials. While the number of patients is too small to permit separate analysis of efficacy and safety, the adverse reactions reported in this population were similar to those reported by younger patients.

ADVERSE REACTIONS: In controlled US studies, 2,427 patients received treatment with intranasal fluticasone propionate. In general, adverse reactions in clinical studies have been primarily associated with irritation of the nasal mucous membranes, and the adverse reactions were reported with approximately the same frequency by patients treated with the vehicle itself. The complaints did not usually interfere with treatment. Less than 2% of patients in clinical trials discontinued because of adverse events; this rate was similar for vehicle and active comparators.

Systemic glucocorticoid side effects were not reported during controlled clinical studies up to 6 months duration with Flonase™ Nasal Spray. If recommended doses are exceeded, however, or if individuals are particularly sensitive or if in conjunction with systemically administered glucocorticoids, symptoms of hypercorticism, e.g., Cushing's syndrome, could occur.

The following incidence of common adverse reactions is based upon seven controlled clinical trials in which 536 patients (57 girls and 108 boys aged 4 to 11 years, 137 female and 234 male adolescents and adults) were treated with Flonase Nasal Spray 200 mcg once daily over 2 to 4 weeks and two controlled clinical trials in which 246 patients (119 female and 127 male adolescents and adults) were treated with Flonase Nasal Spray 200 mcg once daily over 6 months.

Incidence Greater than 1% (Causal Relationship Possible): ***Respiratory:*** Epistaxis, nasal burning (incidence 3% to 6%); blood in nasal mucus, pharyngitis, nasal irritation (incidence 1% to 3%).

Neurological: Headache (incidence 1% to 3%).

Incidence Less than 1% (Causal Relationship Possible): ***Respiratory:*** Sneezing, runny nose, nasal dryness, sinusitis, nasal congestion, bronchitis, nasal ulcer, nasal septum excoriation.

Neurological: Dizziness.

Special Senses: Eye disorder, unpleasant taste.

Digestive: Nausea and vomiting, xerostomia.

Skin and Appendages: Urticaria.

OVERDOSAGE: There are no data available on the effects of acute or chronic overdosage with Flonase™ Nasal Spray. Intranasal administration of 2 mg (10 times the recommended dose) of fluticasone propionate twice daily for 7 days to healthy human volunteers was well tolerated. Single oral doses up to 16 mg have been studied in human volunteers with no acute toxic effects reported. Repeat oral doses up to 80 mg daily for 10 days in volunteers and repeat oral doses up to 10 mg daily for 14 days in patients were well tolerated. Adverse reactions were of mild or moderate severity, and incidences were similar in active and placebo treatment groups. Acute overdosage with this dosage form is unlikely since one bottle of Flonase Nasal Spray contains approximately 8 mg of fluticasone propionate. Chronic overdosage may result in signs/symptoms of hypercorticism (see PRECAUTIONS).

Allen & Hanburys
DIVISION OF GLAXO INC.
Research Triangle Park, NC 27709

October 1994
RL-148
OM.BS.A



Allen & Hanburys
DIVISION OF GLAXO INC.
a world leader in respiratory care
Research Triangle Park, NC 27709

FLN141R0 Printed in USA January 1995

Services Task Force recommendations. *J Fam Pract.* 1992;34:409-416.
3. Scutchfield FD, de Moor C. Preventive attitudes, beliefs, and practices of physicians in fee-for-service and health maintenance organization settings. *West J Med.* 1989;150:221-225.
4. Lewis CE, Wells KB, Ware J. A model for predicting the counseling practices of physicians. *J Gen Intern Med.* 1986;1:14-19.
5. Valente CM, Sobal J, Muncie HL, Levine DM, Antlitz AM. Health promotion: physicians' beliefs, attitudes and practices. *Am J Prev Med.* 1986;2:82-88.
6. Gemson DH, Elinson J. Prevention in primary care: variability in physician practice patterns in New York City. *Am J Prev Med.* 1986;2:226-234.
7. Sobal J, Valente CM, Muncie HL, Levine DM, Deforge BR. Physicians' beliefs about the importance of 25 health promoting behaviors. *Am J Public Health.* 1985;75:1427-1428.
8. McAlister A, Mullen PD, Nixon SA, et al. Health promotion among primary care physicians in Texas. *Tex Med.* 1985;81:55-58.
9. Rosen MA, Logsdon DN, Demak MM. Prevention and health promotion in primary care: baseline results on physicians from the INSURE Project on Lifecycle Preventive Health Services. *Prev Med.* 1984;13:535-548.
10. Wechsler H, Levine S, Idelson RK, Rohman M, Taylor JO. The physician's role in health promotion—a survey of primary-care practitioners. *N Engl J Med.* 1983;308:97-100.
11. Lewis CE, Clancy C, Leake B, Schwartz JS. The counseling practices of internists. *Ann Intern Med.* 1991;114:54-58.
12. Lewis CE. Disease prevention and health promotion practices of primary care physicians in the United States. *Am J Prev Med.* 1988;4(suppl):9-16.
13. Henry RC, Ogle KS, Snellman LA. Preventive medicine: physician practices, beliefs, and perceived barriers for implementation. *Fam Med.* 1987;19:110-113.
14. Orleans CT, George LK, Houpt JL, Brodie KH. Health promotion in primary care: a survey of US family practitioners. *Prev Med.* 1985;14:636-647.
15. Madlon-Kay DJ, Harper PG, Reif CJ. Health promotion counseling in residency training. *J Gen Intern Med.* 1994;9:465-467.
16. Centers for Disease Control and Prevention. CDC surveillance summaries. *MMWR Morb Mortal Wkly Rep.* 1993;42:1-30.
17. Williamson PS, Driscoll CE, Dvorak LD, Garber KA, Shank JC. Health screening examinations: the patient's perspective. *J Fam Pract.* 1988;27:187-192.
18. Stanford JB, Solberg LI. Rural patients' interests in preventive medical care. *J Am Board Fam Pract.* 1991;4:11-18.
19. Romm FJ. Patients' expectations of periodic health examinations. *J Fam Pract.* 1984;19:191-195.
20. Simons-Morton DG, Mullen PD, Mains DA, Tabak ER, Green LW. Characteristics of controlled studies of patient education and counseling for preventive health behaviors. *Patient Educ Couns.* 1992;19:175-204.
21. Shank JC, Powell T, Llewelyn J. A five-year demonstration project associated with improvement in physician health maintenance behavior. *Fam Med.* 1989; 21:273-278.
22. Hahn DL, Berger MG. Implementation of a systematic health maintenance protocol in a private practice. *J Fam Pract.* 1990;31:492-504.
23. Geiger WJ, Neuberger MJ, Bell GC. Implementing the US Preventive Services guidelines in a family practice residency. *Fam Med.* 1993;25:447-451.
24. Belcher DW. Implementing preventive services: success and failure in an outpatient trial. *Arch Intern Med.* 1990;150:2533-2541.
25. Hahn DL. Strategies to promote basic clinical preventive services. *Fam Med.* 1994;26:77.

For Someone Who Stutters, Stage Fright Can Be A Way of Life.



Until he conquered his stuttering problem, stage fright was an everyday occurrence for opera's renowned baritone Robert Merrill. Today he has sung on stages around the world.

If you or someone you know stutters, write or call:

National Stuttering Awareness Week May 8–14

STUTTERING FOUNDATION OF AMERICA

FORMERLY SPEECH FOUNDATION OF AMERICA

A Non-Profit Organization Since 1947—Helping Those Who Stutter

P.O. Box 11749 • Memphis, TN 38111-0749

1-800-992-9392

The Osler Institute
Family Practice Boards Review Course

May 21-27, 1995 – Los Angeles

June 11-17, 1995 – Baltimore July 6-12, 1995 – Chicago

Plus optional day of psychiatry just before and optional day of obstetrics just after

OBJECTIVES

- Improve basic and clinical knowledge in family practice
- Prepare candidates to take Family Practice board exams
- Provide family practitioners with a review and update

METHODS

- SELF-DIRECTED STUDY questions, answers, and assignments
- SEMINAR with projection slides and lecture-note syllabus
- PRACTICE EXAMS with written questions and answers

OPTIONAL DAY BEFORE CORE

Psychiatry

Depression and Mania
Schizophrenia
Anxiety and Neurosis
Personality Disorders
Psych. Emergencies
Alcohol & Drug Abuse
Obesity/Eating Disorders
Sleep Disorders
Geriatric Psychiatry
Psychotherapeutic Drugs

SEVEN DAY CORE COURSE

Medicine and Gerontology

Pulmonology
Asthma and COPD
Pneumonia & Bronchitis
Diffuse Lung Diseases
Pulmonary Emboli
Respiratory Failure

Cardiology
EKG's & Arrhythmias
Preventive Cardiology
Hypertension
Myocardial Infarction
Valvular Disease
Congestive Failure

Gastroenterology
Oral Diseases
Esophageal Problems
Peptic Ulcers
Hepatitis and Cirrhosis
Gallbladder & Pancreas
Chronic Bowel Disease
Anorectal Problems

Nephrology
Acid-Base and 'lytes
Urinary Infections
Renal Failure

Endocrinology
Diabetes Mellitus
Thyroid Diseases
Parathyroid & Adrenal
Osteoporosis

Heme. & Oncology
Anemia
Abnormal White Counts
Bleeding Disorders
Cancer Detection
Cancer Prevention
Primary Care Oncology

Rheum. & Sports
Rheumatic Syndromes
Inflammatory Arthritis
Overuse Injuries
Acute Knee Injuries

Neurology
Headache & Back Pain
Dizziness & Tinnitus
Delirium and Stroke
Dementia & Parkinson's
Epilepsy & Head Injury

Derm. and Pharm.
Common Dermatosis
Systemic Disease Signs
Geriatric Pharmacology
Antibiotic Choices

Potpourri
AIDS and Other STDs
Common Infections
Pain Management
Chest X-ray Review
Abdominal X-rays

Gynecology

Gynecologic Infections
Menstrual Disorders
Pelvic Pain Evaluation
Contraception
Infertility Options
Sexual Assault
Abnormal Pap Smears
Cancer in Women
Menopause Management

Community Med.

Preventive Health Care
Occupational Medicine
Environmental Medicine
Ethical & Legal Issues

Pediatrics

Care of the Newborn
Growth & Development
Vaccinations
Behavior Problems
Learning Disorders
Fever and Infections
Vomiting and Diarrhea
Seizures and Epilepsy
Allergy & Immunology
Common Exanthemas
Child Abuse
Adolescent Medicine

Surgery

Acute Abdomen
Breast Diseases
Trauma Assessment
Vascular Problems
Common Eye Problems
Hand Injuries
Office Orthopedics
Otitis and Sinusitis
Head and Neck Masses
Prostate Problems
Urinary Incontinence

OPTIONAL DAY AFTER CORE

Obstetrics

Prenatal Care
Fetal Testing
Diabetes in Pregnancy
Hypertension
Spontaneous Abortion
Preterm and Post Dates
Induction of Labor
Labor Complications
Obstetric Analgesia
Perinatal Infections
Medical Genetics

May Faculty

Marvin Ament, M.D.
Martin Anderson, M.D.
Daniel Arkfeld, M.D.
Benjamin Banahan, M.D.
J. Bowersox, M.D., Ph.D.
Rodney Camp, M.D.
Henry Cramer, M.D.
Ralph Cutler, M.D.
Mitchell Geffner, M.D.
Charles Goldman, M.D.
David Govaker, M.D.
Arnold Gurevitch, M.D.
Rhoda Hahn, M.D.
Theodore Hall, M.D.
Gregory Herrera, M.D.
Jayson Hymes, M.D.
Abner Korn, M.D.
Kris Kowdley, M.D.
John Lake, M.D.
Jay Lieberman, M.D.
Glen Lillington, M.D.
John McCracken, M.D.
Susan Melvin, D.O.
Laura Mosqueda, M.D.
Lamont Murdoch, M.D.
Anita Nelson, M.D.
Nancy Niparko, M.D.
Arnold Platzker, M.D.
Michael Policar, M.D.
John Pottage, M.D.
James Recabaren, M.D.
Hope Rugo, M.D.
Gary Schiller, M.D.
Sharon Schnare, R.N.
G. M. Silberbach, M.D.
Michael Silver, M.D.
Susan Smiga, M.D.

*"...remarkably complete and pleasant."**

Course Description

Course enrollment is limited to 120 to give personal attention to your questions. Self-directed study questions will be sent before the courses – which will include case reviews and lectures with slides and syllabus and question sessions each evening.

*"Accommodations were comfortable...."**

Locations and Travel

The course will be at the Los Angeles Airport Doubletree Hotel; the Baltimore Washington Airport (BWI) Marriott; and the Radisson Lisle/Naperville – about 20 miles southwest of Chicago's O'Hare Airport. For personal service with travel reservations, please call 800-356-7537 ext. 218.

*"...the most education for the money."**

Fees and Course Hours

Physician or Resident:	Phy.	Res.	Hr.
• 7 Day Core Course	$870	$580	70
Optional Day Before	$150	$100	10
Optional Day After	$150	$100	10
• 9 Day Board Review	$1080	$720	90
Repeating within 2 yrs.	$540	$540	90

- **Add 10% within 10 days of the course.**
- Not in course hotel package add $30 per day.
- A $100 deposit will reserve your position.
- Subject to $100 fee, refunds will be made until the seminar begins.

*"...home study...was extremely helpful."**

AAFP Prescribed Credit

This program has been reviewed and is acceptable up to 88 Prescribed hours by the AAFP. AAFP Prescribed credit is accepted by the AMA as equivalent to AMA PRA Category 1 for the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed hours earned must be reported as Prescribed hours, not as Category 1.

*"I feel [the course] helped me pass...."**

Information

Call Today for information and registration, hotel and travel reservations:

(800) 356-7537 or (812) 299-5658

FAX (812) 299-2775

Limited Enrollment: Family Practice Review Registration

Name _____ Phone _____

Address _____

City/State/Zip _____

☐ April 23-29 – Cincinnati
☐ May 21-27 – Los Angeles
☐ June 11-17 – Baltimore
☐ July 6-12, 1995 – Chicago
☐ Check enclosed $ _____
☐ Please send **FREE SAMPLE**

Mail Today to:

1094 East Dawn Drive, Dept. 505
P.O. Box 2218
Terre Haute, IN 47802-0218

*Comments by Osler participants

ONCE-A-DAY

CARDIZEM® CD

(diltiazem HCl) 120-, 180-, 240-, 300-mg Capsules

FOR HYPERTENSION OR ANGINA

℞ *Cardizem CD Start with one 180-mg capsule daily*

Brief Summary of
Prescribing Information as of April 1993

CARDIZEM® CD
(diltiazem HCl)
Capsules

CONTRAINDICATIONS
CARDIZEM is contraindicated in (1) patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, (2) patients with second- or third-degree AV block except in the presence of a functioning ventricular pacemaker, (3) patients with hypotension (less than 90 mm Hg systolic), (4) patients who have demonstrated hypersensitivity to the drug, and (5) patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission.

WARNINGS
1. **Cardiac Conduction**. CARDIZEM prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second- or third-degree AV block (13 of 3290 patients or 0.40%). Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. A patient with Prinzmetal's angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem.
2. **Congestive Heart Failure**. Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dp/dt). An acute study of oral diltiazem in patients with impaired ventricular function (ejection fraction 24% ± 6%) showed improvement in indices of ventricular function without significant decrease in contractile function (dp/dt). Worsening of congestive heart failure has been reported in patients with preexisting impairment of ventricular function. Experience with the use of CARDIZEM (diltiazem hydrochloride) in combination with beta-blockers in patients with impaired ventricular function is limited. Caution should be exercised when using this combination.
3. **Hypotension**. Decreases in blood pressure associated with CARDIZEM therapy may occasionally result in symptomatic hypotension.
4. **Acute Hepatic Injury**. Mild elevations of transaminases with and without concomitant elevation in alkaline phosphatase and bilirubin have been observed in clinical studies. Such elevations were usually transient and frequently resolved even with continued diltiazem treatment. In rare instances, significant elevations in enzymes such as alkaline phosphatase, LDH, SGOT, SGPT, and other phenomena consistent with acute hepatic injury have been noted. These reactions tended to occur early after therapy initiation (1 to 8 weeks) and have been reversible upon discontinuation of drug therapy. The relationship to CARDIZEM is uncertain in some cases, but probable in some. (See PRECAUTIONS.)

PRECAUTIONS
General
CARDIZEM (diltiazem hydrochloride) is extensively metabolized by the liver and excreted by the kidneys and in bile. As with any drug given over prolonged periods, laboratory parameters of renal and hepatic function should be monitored at regular intervals. The drug should be used with caution in patients with impaired renal or hepatic function. In subacute and chronic dog and rat studies designed to produce toxicity, high doses of diltiazem were associated with hepatic damage. In special subacute hepatic studies, oral doses of 125 mg/kg and higher in rats were associated with histological changes in the liver which were reversible when the drug was discontinued. In dogs, doses of 20 mg/kg were also associated with hepatic changes; however, these changes were reversible with continued dosing.
Dermatological events (see ADVERSE REACTIONS section) may be transient and may disappear despite continued use of CARDIZEM. However, skin eruptions progressing to erythema multiforme and/or exfoliative dermatitis have also been infrequently reported. Should a dermatologic reaction persist, the drug should be discontinued.

Drug Interactions
Due to the potential for additive effects, caution and careful titration are warranted in patients receiving CARDIZEM concomitantly with other agents known to affect cardiac contractility and/or conduction. (See WARNINGS.)
Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with CARDIZEM. (See WARNINGS.)
As with all drugs, care should be exercised when treating patients with multiple medications. CARDIZEM undergoes biotransformation by cytochrome P-450 mixed function oxidase. Coadministration of CARDIZEM with other agents which follow the same route of biotransformation may result in the competitive inhibition of metabolism. Especially in patients with renal and/or hepatic impairment, dosages of similarly metabolized drugs, particularly those of low therapeutic ratio, may require adjustment when starting or stopping concomitantly administered diltiazem to maintain optimum therapeutic blood levels.
Beta-blockers. Controlled and uncontrolled domestic studies suggest that concomitant use of CARDIZEM and beta-blockers is usually well tolerated, but available data are not sufficient to predict the effects of concomitant treatment in patients with left ventricular dysfunction or cardiac conduction abnormalities.
Administration of CARDIZEM (diltiazem hydrochloride) concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%. In vitro, propranolol appears to be displaced from its binding sites by diltiazem. If combination therapy is initiated or withdrawn in conjunction with propranolol, an adjustment in the propranolol dose may be warranted. (See WARNINGS.)
Cimetidine. A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and area-under-the-curve (53%) after a 1-week course of cimetidine at 1200 mg per day and a single dose of diltiazem 60 mg. Ranitidine produced smaller, nonsignificant increases. The effect may be mediated by cimetidine's known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem. Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine. An adjustment in the diltiazem dose may be warranted.
Digitalis. Administration of CARDIZEM with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%. Another investigator found no increase in digoxin levels in 12 patients with coronary artery disease. Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing CARDIZEM therapy to avoid possible over- or under-digitalization. (See WARNINGS.)
Anesthetics. The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers. When used concomitantly, anesthetics and calcium blockers should be titrated carefully.
Cyclosporine. A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients. In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem. If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.
The effect of cyclosporine on diltiazem plasma concentrations has not been evaluated.
Carbamazepine. Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

Carcinogenesis, Mutagenesis, Impairment of Fertility
A 24-month study in rats at oral dosage levels of up to 100 mg/kg/day and a 21-month study in mice at oral dosage levels of up to 30 mg/kg/day showed no evidence of carcinogenicity. There was also no mutagenic response in vitro or in vivo in mammalian cell assays or in vitro in bacteria. No evidence of impaired fertility was observed in a study performed in male and female rats at oral dosages of up to 100 mg/kg/day.

Pregnancy
Category C. Reproduction studies have been conducted in mice, rats, and rabbits. Administration of doses ranging from five to ten times greater (on a mg/kg basis) than the daily recommended therapeutic dose has resulted in embryo and fetal lethality. These doses, in some studies, have been reported to cause skeletal abnormalities. In the perinatal/postnatal studies, there was an increased incidence of stillbirths at doses of 20 times the human dose or greater.
There are no well-controlled studies in pregnant women; therefore, use CARDIZEM in pregnant women only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers
Diltiazem is excreted in human milk. One report suggests that concentrations in breast milk may approximate serum levels. If use of CARDIZEM is deemed essential, an alternative method of infant feeding should be instituted.

Pediatric Use
Safety and effectiveness in children have not been established.

ADVERSE REACTIONS
Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded from these studies.
The following table presents the most common adverse reactions reported in placebo-controlled angina and hypertension trials in patients receiving CARDIZEM CD up to 360 mg with rates in placebo patients shown for comparison.

CARDIZEM CD Capsule Placebo-Controlled Angina and Hypertension Trials Combined

Adverse Reactions	Cardizem CD (n=607)	Placebo (n=301)
Headache	5.4%	5.0%
Dizziness	3.0%	3.0%
Bradycardia	3.3%	1.3%
AV Block First Degree	3.3%	0.0%
Edema	2.6%	1.3%
ECG Abnormality	1.6%	2.3%
Asthenia	1.8%	1.7%

In clinical trials of CARDIZEM CD capsules, CARDIZEM tablets, and CARDIZEM SR capsules involving over 3200 patients, the most common events (ie, greater than 1%) were edema (4.6%), headache (4.6%), dizziness (3.5%), asthenia (2.6%), first-degree AV block (2.4%), bradycardia (1.7%), flushing (1.4%), nausea (1.4%), and rash (1.2%).
In addition, the following events were reported infrequently (less than 1%) in angina or hypertension trials:
Cardiovascular: Angina, arrhythmia, AV block (second- or third-degree), bundle branch block, congestive heart failure, ECG abnormalities, hypotension, palpitations, syncope, tachycardia, ventricular extrasystoles
Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tinnitus, tremor
Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dysgeusia, dyspepsia, mild elevations of SGOT, SGPT, LDH, and alkaline phosphatase (see hepatic warnings), thirst, vomiting, weight increase
Dermatological: Petechiae, photosensitivity, pruritus, urticaria
Other: Amblyopia, CPK increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, sexual difficulties
The following postmarketing events have been reported infrequently in patients receiving CARDIZEM: alopecia, erythema multiforme, exfoliative dermatitis, extrapyramidal symptoms, gingival hyperplasia, hemolytic anemia, increased bleeding time, leukopenia, purpura, retinopathy, and thrombocytopenia. In addition, events such as myocardial infarction have been observed which are not readily distinguishable from the natural history of the disease in these patients. A number of well-documented cases of generalized rash, characterized as leukocytoclastic vasculitis, have been reported. However, a definitive cause and effect relationship between these events and CARDIZEM therapy is yet to be established.

Prescribing Information as of April 1993

Marion Merrell Dow Inc.
Kansas City, MO 64114

ccdb0493a

References: 1. Cardizem CD prescribing information. **2.** Data on file, Marion Merrell Dow Inc.

MARION MERRELL DOW INC.
U S A
KANSAS CITY, MO 64114

CVM94013001

1405E4

IN HYPERTENSION OR ANGINA

CARDIZEM® CD

(diltiazem HCl) 120-, 180-, 240-, 300-mg Capsules

FOR EFFECTIVE 24-HOUR CONTROL

ONCE A DAY

A unique hemodynamic and safety profile for hypertension or angina[1,2]

- A side-effect discontinuation rate comparable to placebo in both hypertension and angina trials[2]
- Most commonly reported side effects are headache (5.4%), bradycardia (3.3%), first-degree AV block (3.3%), dizziness (3.0%), edema (2.6%), ECG abnormality (1.6%), and asthenia (1.8%)[1]

Please see brief summary of prescribing information on adjacent page.